Hasbro Children's Hospital, Providence, RI. RATIONALE: About 10% of patients report allergy to penicillin. Of those patients evaluated with a penicillin skin test (ST) and challenge, 90-99% are able to tolerate penicillin, resulting in penicillin allergy de-labeling. However, while patients are often de-labeled in the short term, factors that predict the persistence of penicillin allergy de-labeling remain unknown. METHODS: A retrospective chart review was conducted on patients evaluated for penicillin allergy from 2012-2017(inpatient and outpatient). Data was collected from the electronic medical record (EMR), pharmacy records, as well as a follow-up telephone survey with patients. RESULTS: Thirty-three patients were successfully de-labeled of their penicillin allergy (negative ST and tolerated oral challenge). One-third of these patients had persistence of their penicillin allergy in the EMR (11/ 33), and 7 patients had persistence in their pharmacy records (21%). Persistence of the penicillin allergy label was not significantly associated with age (p50.73), gender (p50.35), or whether the evaluation was done inpatient or outpatient (p50.88). Follow-up telephone survey was done with 24 patients (nine patients were unavailable for follow-up), and 96% (n523) recalled the results of their allergy evaluation correctly. Despite accurate recall, 3 patients continued to avoid penicillin for fear of a possible reaction. CONCLUSIONS: This study found that while penicillin allergy delabeling is safe and effective, there is a discrepancy between the allergy evaluation and the appropriate removal of the penicillin allergy from the EMR and pharmacy records, which may include patient apprehension as a cause. Neither age, gender, nor place of evaluation predicted persistence of the penicillin allergy label. Room 418, Vanderbilt University Medical Center, Nashville, TN. RATIONALE: Gastrointestinal symptoms are the most common side effect leading to discontinuation of aspirin therapy in patients with aspirinexacerbated respiratory disease (AERD). Some patients with gastrointestinal symptoms on high-dose aspirin demonstrated biopsy-proven esophageal eosinophilia (EE). In a large cohort of patients with AERD we report on this novel clinical entity. METHODS: Charts from 387 patients enrolled in the Brigham and Women's Hospital AERD registry were reviewed for history of biopsyproven EE. All subjects were diagnosed with AERD by a Partners Healthcare physician. Data was analyzed using student's t-test and chisquare tests where appropriate. RESULTS: 13 (3.4%) patients had a history of biopsy-proven EE documented in the medical chart. 10 of 13 were desensitized to aspirin with 9 of them first developing EE 3 months to 6 years after aspirin initiation. AERD subjects with EE demonstrated greater rates of gastric irritation at follow-up visits (p<0.001) and of aspirin discontinuation due to gastric irritation (p50.013, Pearson's Chi-Squared test) than the non-EE group. Those with EE reported a faster rate of nasal polyp regrowth compared to the non-EE group (4.7563.35 versus 14.9620.8 months, p<.0001). CONCLUSIONS: Our study is the first to explore the relationship between aspirin therapy in AERD and the development of EE. We observed that EE develops in subjects with AERD both before and after initiation of daily aspirin therapy with more cases reported after starting aspirin. We found that the presence of EE is associated with faster regrowth of nasal polyps suggesting more severe sino-nasal mucosal pathology in this population. RATIONALE: Evaluate the characteristics of self-reported NSAID hypersensitivity and identify patients at high risk of NSAID hypersensitivity.
Room 418, Vanderbilt University Medical Center, Nashville, TN. RATIONALE: Gastrointestinal symptoms are the most common side effect leading to discontinuation of aspirin therapy in patients with aspirinexacerbated respiratory disease (AERD). Some patients with gastrointestinal symptoms on high-dose aspirin demonstrated biopsy-proven esophageal eosinophilia (EE). In a large cohort of patients with AERD we report on this novel clinical entity. METHODS: Charts from 387 patients enrolled in the Brigham and Women's Hospital AERD registry were reviewed for history of biopsyproven EE. All subjects were diagnosed with AERD by a Partners Healthcare physician. Data was analyzed using student's t-test and chisquare tests where appropriate. RESULTS: 13 (3.4%) patients had a history of biopsy-proven EE documented in the medical chart. 10 of 13 were desensitized to aspirin with 9 of them first developing EE 3 months to 6 years after aspirin initiation. AERD subjects with EE demonstrated greater rates of gastric irritation at follow-up visits (p<0.001) and of aspirin discontinuation due to gastric irritation (p50.013, Pearson's Chi-Squared test) than the non-EE group. Those with EE reported a faster rate of nasal polyp regrowth compared to the non-EE group (4.7563.35 versus 14.9620.8 months, p<.0001). CONCLUSIONS: Our study is the first to explore the relationship between aspirin therapy in AERD and the development of EE. We observed that EE develops in subjects with AERD both before and after initiation of daily aspirin therapy with more cases reported after starting aspirin. We found that the presence of EE is associated with faster regrowth of nasal polyps suggesting more severe sino-nasal mucosal pathology in this population. 
METHODS:
Patients who presented at Songklanagarind Hospital between January-December 2017 with reported NSAID-hypersensitivity were evaluated. Clinical information obtained from a review of medical records was further supplemented with data gained from a telephoneadministered questionnaire. RESULTS: From a total of 535 patients with reported NSAID hypersensitivity, 301 were included in the study. The mean age of onset of NSAID hypersensitivity reaction was 30.3 6 14.9 years old, and 65.1% were female. A total of 84 patients (27.9%) were hypersensitive to 2 or more chemically-unrelated NSAIDs. NSAID hypersensitivity was to propionic acid derivatives (73%) followed by acetic acid derivatives (28.9%). Immediate reaction(< _1 hour) was identified in 171 patients (57.8%) and angioedema was the most frequently reported symptom (179 patients, 59.5%), followed by urticaria and anaphylaxis in 85 (28.2%) and 62 (20.6%) patients, respectively. DPT test was performed on 53 patients, and NSAID hypersensitivity was confirmed in 38 patients (71.6%). Independent factors identified which could predict NSAID hypersensitivity were personal history of allergic rhinitis/chronic rhinosinusitis, onset of NSAID hypersensitivity over 15 years old, and immediate reaction. CONCLUSIONS: Angioedema was the most typical symptom and propionic acid derivatives were the most frequently reported culprit drugs. The significant risk factors predicting NSAIDs hypersensitivity were personal history of AR/CRS, onset of NSAID hypersensitivity reaction over 15 years old, and immediate reaction.
